Candriam S.C.A. Has $10.79 Million Stock Holdings in Elevance Health, Inc. $ELV

Candriam S.C.A. reduced its position in shares of Elevance Health, Inc. (NYSE:ELV) by 15.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 36,861 shares of the company’s stock after selling 6,979 shares during the period. Candriam S.C.A.’s holdings in Elevance Health were worth $10,791,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in ELV. Kemnay Advisory Services Inc. bought a new stake in Elevance Health during the 4th quarter worth approximately $31,000. J.Safra Asset Management Corp acquired a new position in Elevance Health in the 4th quarter valued at approximately $32,000. ORG Partners LLC raised its stake in shares of Elevance Health by 120.4% during the fourth quarter. ORG Partners LLC now owns 108 shares of the company’s stock valued at $38,000 after acquiring an additional 59 shares during the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new position in shares of Elevance Health during the fourth quarter valued at $38,000. Finally, Dorato Capital Management acquired a new position in shares of Elevance Health during the fourth quarter worth $41,000. Institutional investors own 89.24% of the company’s stock.

Insider Activity

In related news, Director Robert L. Dixon, Jr. sold 151 shares of the company’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $401.77, for a total transaction of $60,667.27. Following the sale, the director owned 10,734 shares in the company, valued at $4,312,599.18. This represents a 1.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.34% of the stock is owned by corporate insiders.

Elevance Health Price Performance

Shares of NYSE ELV opened at $416.54 on Monday. Elevance Health, Inc. has a twelve month low of $273.71 and a twelve month high of $427.64. The firm has a fifty day simple moving average of $397.16 and a 200 day simple moving average of $353.55. The company has a market capitalization of $90.46 billion, a PE ratio of 17.72, a P/E/G ratio of 2.36 and a beta of 0.67. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70.

Elevance Health (NYSE:ELV) last released its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $1.84. The business had revenue of $49.49 billion for the quarter, compared to analyst estimates of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. Elevance Health’s revenue for the quarter was up 1.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $11.97 earnings per share. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, sell-side analysts forecast that Elevance Health, Inc. will post 26.86 EPS for the current year.

Elevance Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th were paid a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date of this dividend was Wednesday, June 10th. Elevance Health’s payout ratio is currently 29.26%.

Analysts Set New Price Targets

ELV has been the topic of several analyst reports. UBS Group boosted their price objective on shares of Elevance Health from $400.00 to $460.00 and gave the stock a “buy” rating in a research note on Friday, May 22nd. Leerink Partners set a $364.00 target price on Elevance Health in a research report on Thursday, April 23rd. Mizuho lifted their target price on Elevance Health from $435.00 to $465.00 and gave the stock an “outperform” rating in a report on Monday, June 8th. Guggenheim upped their price target on Elevance Health from $396.00 to $399.00 and gave the company a “buy” rating in a research report on Friday, April 24th. Finally, Jefferies Financial Group decreased their price target on Elevance Health from $395.00 to $391.00 and set a “buy” rating for the company in a research note on Monday, April 20th. Fifteen investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $425.95.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.